VCYT

Veracyte, Inc.

September 24, 2026 · intraday

Rarity

2.01

Peak move

+11.13%

Float cap

$3.4B

Veracyte, Inc. is a global diagnostics company that sells molecular diagnostic tests to clinicians and patients to guide cancer diagnosis, prognosis, and treatment. In the United States, it offers laboratory-developed tests through its CLIA-certified labs, including Decipher Prostate, Afirma, Prosigna, and Decipher Bladder. Outside the United States, it distributes in vitro diagnostic tests to laboratories and hospitals.

• insider_saleSep 24 · 16:25 ET

  Director Jens Holstein filed notice to sell 7,500 shares of Veracyte common stock at an average price of $47.00, a proposed sale valued at $352,500 under a 10b5-1 plan.

  SEC144 0001950047-26-009791
• insider_saleSep 22 · 17:16 ET

  Veracyte Global Chief Commercial Officer John Leite sold 4,015 shares at $40.00 per share on September 21, 2026 for about $160,600 under a Rule 10b5-1 plan adopted June 9, 2026, leaving him 124,329 shares directly held, per a Form 4 filed September 22, 2026.

  SEC4 0001991536-26-000013Webkalkine.comWebmarketbeat.comWebsec.gov
• institutional_flowSep 22 · 07:10 ET

  ARK Invest's ARK Genomic Revolution ETF (ARKG) bought 74,878 Veracyte shares worth about $2.98 million in its September 21, 2026 daily trade disclosure, alongside purchases of Ionis, Beam and Scribe Therapeutics.

  Webapp.myzaker.comWebstocktwits.com